SCHEMBL6372683

SCHEMBL6372683

CCc1cc(-c2ccc(CNCc3ccccc3)o2)c(C)[nH]c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LDHA P00338 1/20 0.44
▸ LDHB P07195 1/20 0.44
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ S1PR1 P21453 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ KDM4E B2RXH2 7/20 0.38
▸ ALDH1A1 P00352 6/20 0.38
▸ HPGD P15428 4/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ LMNA P02545 3/20 0.37
▸ HTT P42858 2/20 0.37
▸ PARP1 P09874 1/20 0.36
▸ GAA P10253 4/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ GPR55 Q9Y2T6 1/20 0.36
▸ CDC7 O00311 1/20 0.36
▸ CCNE1 P24864 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ ROCK1 Q13464 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2673379 0.99 LDHA (0.43) LDHALDHBCA1CA2S1PR1
SCHEMBL2673808 0.90 HTR6 (0.40) S1PR1GAAMAPT
SCHEMBL2673369 0.84 RAB9A (0.38) LDHALDHBNPC1ALDH1A1HPGD
SCHEMBL2674239 0.84 TP53 (0.40) NPC1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2674415 0.82 ALDH1A1 (0.35) S1PR1NPC1KDM4EALDH1A1LMNA
SCHEMBL2673206 0.81 ALDH1A1 (0.41) S1PR1NPC1KDM4EALDH1A1HPGD
SCHEMBL6372416 0.81 HSD17B10 (0.42) S1PR1NPC1KDM4EALDH1A1HPGD
SCHEMBL2673521 0.81 ALDH1A1 (0.38) NPC1KDM4EALDH1A1LMNAGAA
Cyclopentane SCHEMBL14142670 0.80 ALDH1A1 (0.34) S1PR1NPC1KDM4EALDH1A1HPGD
SCHEMBL14586088 0.79 GAA (0.34) CA1CA2GAACDK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732896-B1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMA INC (US) 2012-12-12 — — EP claimed
EP-1732896-B1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMA INC (US) 2012-12-12 — — EP disclosed
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-08-09 — — US disclosed
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-08-09 — — US disclosed
US-8173682-B2 Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-05-08 — — US disclosed
US-8173682-B2 Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-05-08 — — US disclosed
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2007-02-08 — — US disclosed
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP3 LDHA 1579/4885LDHB 1615/4885CA1 4845/4885
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP3 LDHA 1579/4885LDHB 1615/4885CA1 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback